The global immuno-oncology market is projected to grow at a robust CAGR of approximately 21% over the next five years. This strong expansion is fueled by the rising global cancer burden, continuous ...

Syncromune is advancing SYNC-T Therapy SV-102 in the ongoing Phase 2 LEGION-100 study (NCT06533644), which is actively enrolling across multiple sites in the U.S. Please visit www.legion100trial.com ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with ...

Every single type of cancer, explained A cancer diagnosis can be both terrifying and confusing for those afflicted, as well ...

The "Provenge Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The report outlines essential statistics, market ...

Cross-trial analyses comparing ANKTIVA + BCG with nadofaragene firadenovec-vncg and TAR-200 provide important context, ...

India, April 30 -- Cancer is no longer just an older-age issue. Younger adults are seeing more cancer despite improvements in ...

Dendritic cells (DCs) have emerged in the field of cancer immunotherapy as the most potent professional antigen-presenting ...

Rani Bansal, MD, discusses breast cancer subtypes, racial disparities in triple-negative disease, self-advocacy for young ...

Is the pain of chemotherapy and radiation a thing of the past? A revolutionary new treatment called 'Cryoablation' or 'Cryotherapy' is here. This method literally freezes cancer cells to death at ...

Detailed price information for Coherus Oncology Inc (CHRS-Q) from The Globe and Mail including charting and trades.